Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Neuroblastoma 1Lymphoma 1Leukemia 1Immunologic Deficiency Syndromes 1Anemia 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × fosphenytoin × Clear all
NCT00801931 2019-03-27

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Columbia University

Phase 1/2 Terminated
1 enrolled 8 charts
CNSClassical hematologyLymphoidOther hematologic neoplasm

Anemia, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡